GlassScriptPhysician profile
Melissa M Carter
NPI 1881634442
$8,943.13
in general payments reported to CMS, 2019-2025
36 companies · $978 in 2025
The $978 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,963 · 2022: $1,827 · 2023: $1,814 · 2024: $2,361 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,143 · Travel and Lodging: $1,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,142.78 |
| Travel and Lodging | $1,009.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,051.19 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Intuitive Surgical, INC. | $1,009.92 | 2024 | |
| Abbvie INC. | $930.74 | 2021-2025 | |
| Mannkind Corporation | $871.84 | 2021-2023 | Afrezza |
| Lilly USA, LLC | $690.31 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $502.05 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $421.48 | 2021-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $321.61 | 2021-2025 | |
| Amgen INC. | $310.81 | 2021-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $234.68 | 2021-2024 | Farxiga, Breztri, Lokelma |
| Biohaven Pharmaceutical Holding Company LTD. | $162.02 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $151.34 | 2021 | |
| Shield Therapeutics INC | $141.24 | 2023-2024 | Accrufer |
| Exact Sciences Corporation | $115.07 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $102.44 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $99.52 | 2021-2023 | Nexletol |
| Astellas Pharma US INC | $97.88 | 2024-2025 | Veozah |
| Insulet Corporation | $82.19 | 2021-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.67 | 2021-2023 | Jardiance |
| Zealand Pharma US, INC. | $73.98 | 2021-2022 | |
| Stryker Corporation | $68.44 | 2024 | Prostep Mica, Hoffmann |
| Novartis Pharmaceuticals Corporation | $59.57 | 2021 | |
| Idorsia Pharmaceuticals US INC | $43.39 | 2023-2024 | Quviviq |
| Rgh Enterprises LLC | $41.99 | 2025 | |
| Hologic Sales and Service, LLC | $37.05 | 2025 | Aptima |
| Inspire Medical Systems, INC. | $33.36 | 2024 | Inspire |
| Beta Bionics, INC. | $28.60 | 2024 | Ilet Bionic Pancreas |
| Alexion Pharmaceuticals, INC. | $26.65 | 2022 | |
| Bausch Health US, LLC | $23.80 | 2022 | |
| Dexcom, INC. | $23.15 | 2024 | Dexcom G6 Transmitter |
| Endogastric Solutions, INC | $21.03 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.72 | 2024 | Voquezna |
| Tandem Diabetes Care, INC. | $18.30 | 2022 | |
| Sanofi Pasteur INC. | $18.24 | 2025 | |
| Sunovion Pharmaceuticals INC. | $16.83 | 2022 | |
| Abbott Laboratories | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.